Optimizing Outcomes with Currently Available Therapies – The Regulatory Standard Is the Treatment Standard

Explore treatment strategies for platinum-sensitive and platinum-resistant recurrent ovarian cancer, comparing optimization of outcomes with currently available therapies versus incorporation of emerging agents. Faculty will review clinical trial data, response patterns, and toxicity considerations across these approaches, providing expert perspectives on integrating established and emerging therapies to improve outcomes in recurrent ovarian cancer. This session will focus on optimizing outcomes for patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer using currently available therapies, and will review evidence supporting established chemotherapy regimens, targeted agents, and maintenance strategies across disease settings. Discussion will address sequencing, toxicity management, and tailoring treatment based on platinum sensitivity and prior therapy.